Comparative Pharmacology
Head-to-head clinical analysis: DOXYCYCLINE versus MINOLIRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYCYCLINE versus MINOLIRA.
DOXYCYCLINE vs MINOLIRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. It also exhibits anti-inflammatory and anti-collagenase activities.
Sodium-glucose co-transporter-2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg every 12 hours or 50 mg every 6 hours.
60 mg subcutaneously once daily
None Documented
None Documented
Terminal elimination half-life is 18–24 hours in patients with normal renal function; prolonged to 20–30 hours in renal impairment; allows once or twice daily dosing.
Clinical Note
moderateMethoxsalen + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Methoxsalen."
Clinical Note
moderateCyclophosphamide + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Cyclophosphamide."
Clinical Note
moderatePaclitaxel + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Paclitaxel."
Clinical Note
moderateDocetaxel + Doxycycline
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
Renal (40%) and fecal/biliary (60%); undergoes enterohepatic circulation; active drug and metabolites excreted in urine and feces.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 25%; the remainder undergoes hepatic metabolism.
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic
"The metabolism of Doxycycline can be decreased when combined with Docetaxel."